A Munich-based biotech venture called Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”) focusing on the discovery and development of next generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAPlus™...